SET has also been recognized as a prognostic marker for poor overall survival in AML [22, 24], although the exact molecular mechanisms linking a SET oncoprotein pathway with aggressive AML outcomes remain still obscure. This evidence concerns the gene SET and acute myeloid leukemia.